Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5395-5404
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5395
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5395
Table 2 Clinical outcomes of the nine patients
Patient | Change of AFP | AFP before treatment | AFP after first cycle | AFP after second cycle | AFP after third cycle | Radiological evaluation |
P1 | ↓ | 168.5 | 118.0 | 29.7 | 27.3 | PR |
P2 | ↓ | 94.9 | 53.8 | 59.8 | 50.2 | PR |
P3 | ↓ | 4942.3 | 3297.1 | 3180.0 | - | PR |
P4 | ↓ | 1691.6 | 619.7 | 312.2 | 302.0 | SD |
P5 | ↓ | 45.7 | 25.9 | 24.1 | - | SD |
P6 | ↓ | 11.6 | 1.7 | 2.9 | - | SD |
P7 | ↑ | 1029.7 | 1700.0 | 3800.0 | 3818.3 | PD |
P8 | ↑ | 737.8 | 2005.6 | - | - | PD |
P9 | ↑ | 157.5 | 294.1 | 248.0 | - | PD |
- Citation: Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5395.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5395